Subscribe To
Masonic cancer center, university of minnesota to present data in poster presentation human data readout for phase 1 study to evaluate hcw9218 in solid tumors at sitc 38th annual meeting
HCW9218 is the lead product candidate of HCW Biologics Inc. MIRAMAR, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or...
November 1, 2023, 11:30 am
Sensei biotherapeutics appoints stephanie krebs, ms, mba, as chief business officer
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discov...
November 1, 2023, 11:30 am
Springworks therapeutics announces presentation of additional data from phase 3 defi trial of nirogacestat in adults with desmoid tumors at the 2023 ctos annual meeting
– Nirogacestat Treatment Demonstrated Rapid and Sustained Improvements in Functional Status Compared to Placebo Across Multiple Assessment Tools –...
November 1, 2023, 10:30 am
Why is mainz biomed (mynz) stock moving today?
Mainz Biomed (NASDAQ: MYNZ ) stock is on the move Wednesday after the molecular genetics cancer diagno...
November 1, 2023, 8:40 am
Affimed to participate in upcoming investor conferences
MANNHEIM, Germany, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncolog...
November 1, 2023, 6:30 am
Scancell melanoma trial data chosen for poster presentation at sitc
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) told investors that it has been selected for a poster presentation of data from the first stage of its Pha...
November 1, 2023, 4:16 am
Astrazeneca inks gene editing deal that could end up costing it $2.5bn
AstraZeneca PLC (LSE:AZN) has entered into a partnership and investment deal with French gene editing specialist biotech firm Cellectis (NASDAQ:CLLS) ...
November 1, 2023, 3:59 am
Poolbeg investor meeting will take a deep dive into lead programme
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) is hosting an investor and analyst meeting focusing on its POLB 001 Oncology Programme, targeting cytokin...
November 1, 2023, 3:34 am
Bayer ordered to pay $332 mln in roundup cancer trial -law.com
A California jury found Bayer liable in a case brought by a man who claimed his cancer was due to expos...
October 31, 2023, 7:46 pm
Mersana therapeutics to host third quarter 2023 conference call on november 7, 2023
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on d...
October 31, 2023, 4:30 pm
Revolution medicines to report financial results for third quarter 2023 after market close on november 6, 2023
REDWOOD CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel ...
October 31, 2023, 4:15 pm
Pfizer to sees no major m&a activity in 2024: ceo bourla
Pfizer Chairman and CEO Albert Bourla says the company is still in the market for acquisitions following its $43 billion acquisition of ...
October 31, 2023, 3:30 pm
Analyzing the acquisition potential of immunogen
ImmunoGen, Inc.'s marketing authorization application for ELAHERE, a cancer therapy, has been accepted ...
October 31, 2023, 3:25 pm
Drugmaker incyte's quarterly profit beats on lower costs
Incyte reported a third-quarter profit on Tuesday that beat analysts' estimates as lower costs helped offset weak sales of its blood ...
October 31, 2023, 9:48 am
Xilio to host virtual investor conference call and webcast on monday, november 6, 2023 to review progress across pipeline, including phase 1/2 clinical data for xtx202, a tumor-activated, engineered,
WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and devel...
October 31, 2023, 9:15 am
Iovance biotherapeutics to present clinical and pre-clinical data for tumor infiltrating lymphocyte (til) therapies at society for tumor immunotherapy of cancer's (sitc) 38th annual meeting
SAN CARLOS, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, dev...
October 31, 2023, 9:05 am
Perimeter medical imaging ai initiates new clinical trial site at university of washington's fred hutch cancer center
Perimeter Medical Imaging AI (TSX-V:PINK, OTC:PYNKF) said it has initiated an additional clinical trial site at the Fred Hutch ...
October 31, 2023, 8:08 am
Scancell makes strong progress with lead immunotherapy assets
Key highlights for biotech group Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF)'s financial year ending April 30 included a positive data reading arising...
October 31, 2023, 4:48 am
Transcode therapeutics withdraws public offering
BOSTON, Oct. 30, 2023 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (the “Company”), the RNA oncology company committed to more...
October 30, 2023, 8:33 pm
Atossa therapeutics' (z)-endoxifen being evaluated as alternative treatment for ductal carcinoma in situ
Atossa Therapeutics Inc (NASDAQ:ATOS)'s selective estrogen receptor modulator (Z)-endoxifen is being evaluated in a Phase 2 study aimed at preventing ...
October 30, 2023, 3:11 pm